Center for Breakthrough Medicines Beats Back on the 2022 Biotech Bear Market with Rapid Hiring and Expansion

Published on :

Audrey Greenberg, co-founder of CBM and also the executive director of The Discovery Labs, said the successful growth seen at CBM is a testament to the great company culture the organization has built since its founding in 2019. Among the hires in the first quarter of this year is John Lee, PhD, the new Vice President and Head of Cell Therapy. Lee, an accomplished CAR-T immunobiologist, was hired in March to lead cell therapy programs at CBM. Prior to joining CBM, Lee established the Cell Therapy Platform team at Janssen Pharmaceuticals. He also served as head of Oncology Cell Therapy at GlaxoSmithKline.

A team at Penn says it has slashed CAR-T cell therapy manufacturing timeframe to just 24 hours

Published on :

The future of CAR-T cell therapy research has come a long way over the years, but scientists have still been plagued by one problem: how to cut down on the timeframe, which typically takes between 9 and 14 days.
Except now. Researchers at Penn say that they have shortened the process, enhancing anti-tumor potency in just 24 hours. The preclinical study, carried out by researchers Michael Milone and Saba Ghassemi, has been published in Nature Biomedical Engineering. The results show the potential for a stark reduction of time, materials and labor that’s required to make CAR-T cells, which could be the most beneficial for those who are experiencing rapidly-progressing disease in environments with limited resources.

Verismo Therapeutics, Inc., Enters into Master Translational Research Services Agreement with the University of Pennsylvania

Published on :

Verismo Therapeutics, Inc., a recent University of Pennsylvania spinout researching and developing a novel multichain KIR-CAR platform technology for CAR T cells, announced the signing of a Master Translational Research Services Agreement to, in part, establish a manufacturing partnership with organizations within the Perelman School of Medicine at the University of Pennsylvania (Penn), including a vector manufacturing facility at the Center for Advanced Retinal & Ocular Therapeutics (CAROT).

CRB Group Has Hand in Providing Space for Philadelphia’s Life Sciences Ecosystem

Published on :

The Amicus facility encompasses 75,000 square feet of the top three floors of a new building located on Market Street in Philadelphia. The space includes office space, as well as state-of-the-art laboratories. It’s expected to provide space for approximately 200 researchers and drug developers focused exclusively on gene therapies. 

Regional Collaborations Emerge to Address the Biomanufacturing Workforce Crisis

Published on :

We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.

Gyroscope’s “Vision for Life” Eyes $100M+ IPO

Published on :

Gyroscope Therapeutics, a gene therapy company developing treatments for eye diseases, filed a Form F-1 with the U.S. Securities and Exchange Commission announcing its intention to begin selling American Depository Shares on the Nasdaq Exchange under the ticker symbol “VISN.” At the time of its filing this week, Gyroscope said it has not yet set the pricing terms for its stock. The $100 million is a placeholder figure. Based on positive clinical activity, and a recent financing round, the company is likely to raise significantly more than $100 million.

5 Questions with Neil Sheppard, Immunologist, University of Pennsylvania

Published on :

Neil Sheppard is an Immunologist educated in the UK at the Universities of Bristol and Oxford. He has over 18 years’ experience in the fields of vaccines and immunotherapies, including over a dozen years leading drug discovery and development programs in Big Pharma and Biotech.

UK Biotech Companies Thriving in Maryland and Philadelphia Hubs

Published on :

For decades, the United States and the United Kingdom have enjoyed a special relationship that crosses political, economic, and military lines. But, the two nations also share a similar comradery in the Life Sciences arena, and prominent biotech hubs like the BioHealth Capital Region and Philadelphia showcase that connection.